CA3072353A1 - Usp7 inhibitors for treating multiple myeloma - Google Patents
Usp7 inhibitors for treating multiple myeloma Download PDFInfo
- Publication number
- CA3072353A1 CA3072353A1 CA3072353A CA3072353A CA3072353A1 CA 3072353 A1 CA3072353 A1 CA 3072353A1 CA 3072353 A CA3072353 A CA 3072353A CA 3072353 A CA3072353 A CA 3072353A CA 3072353 A1 CA3072353 A1 CA 3072353A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- compound
- heteroaryl
- aryl
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762563375P | 2017-09-26 | 2017-09-26 | |
| US62/563,375 | 2017-09-26 | ||
| PCT/US2018/052797 WO2019067503A1 (en) | 2017-09-26 | 2018-09-26 | NEW USP7 INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3072353A1 true CA3072353A1 (en) | 2019-04-04 |
Family
ID=65903565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3072353A Pending CA3072353A1 (en) | 2017-09-26 | 2018-09-26 | Usp7 inhibitors for treating multiple myeloma |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11465983B2 (enExample) |
| EP (1) | EP3687537A4 (enExample) |
| JP (3) | JP7402792B2 (enExample) |
| AU (1) | AU2018342089B2 (enExample) |
| CA (1) | CA3072353A1 (enExample) |
| WO (1) | WO2019067503A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018342089B2 (en) | 2017-09-26 | 2024-07-11 | Dana-Farber Cancer Institute, Inc. | Novel USP7 inhibitors for treating multiple myeloma |
| EP3870179A4 (en) * | 2018-10-22 | 2022-11-23 | Dana Farber Cancer Institute, Inc. | USP7 ESCAPEMENT |
| JP2022510700A (ja) * | 2018-12-06 | 2022-01-27 | アルマック・ディスカバリー・リミテッド | 治療において使用するｕｓｐ１９阻害剤 |
| CA3134564A1 (en) * | 2019-05-06 | 2020-11-12 | Lawrence Marcin | Inhibiting usp19 |
| WO2021170290A1 (en) | 2020-02-28 | 2021-09-02 | Immunologik Gmbh | Inhibitors of human deubiquitinases for the treatment of coronaviral infections |
| CN112047933B (zh) * | 2020-10-15 | 2022-06-14 | 郑州大学 | 喹唑啉酮类usp7抑制剂及其制备方法和应用 |
| GB202104097D0 (en) * | 2021-03-24 | 2021-05-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| JP2024526849A (ja) * | 2021-07-20 | 2024-07-19 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | ユビキチン特異的プロテアーゼ７（ｕｓｐ７）を標的とする阻害剤 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5679398A (en) | 1997-01-31 | 1998-08-25 | Kyowa Hakko Kogyo Co. Ltd. | Piperidine derivatives |
| JPH11171774A (ja) | 1997-12-05 | 1999-06-29 | Kyowa Hakko Kogyo Co Ltd | 血球増多剤 |
| WO1999053924A1 (en) * | 1998-04-17 | 1999-10-28 | Kyowa Hakko Kogyo Co., Ltd. | Analgetic agent |
| CA2476583C (en) | 2002-03-13 | 2011-07-05 | Kristof Van Emelen | Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
| JP5415942B2 (ja) | 2006-06-22 | 2014-02-12 | プラナ バイオテクノロジー リミティッド | 処置の方法およびその処置に有用な薬剤 |
| EP2565186A1 (en) * | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| TWI698436B (zh) | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶 |
| MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
| HK1248221A1 (zh) | 2015-02-05 | 2018-10-12 | Forma Therapeutics, Inc. | 异噻唑啉酮类，吡唑并嘧啶酮类和吡咯并嘧啶酮作为泛蛋白特异性蛋白酶7抑制剂 |
| EP3253765A1 (en) * | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors |
| EP3253738A1 (en) * | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors |
| GB201612938D0 (en) | 2016-07-26 | 2016-09-07 | Almac Discovery Ltd | Pharmaceutical compounds |
| GB201617758D0 (en) | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| AU2018342089B2 (en) | 2017-09-26 | 2024-07-11 | Dana-Farber Cancer Institute, Inc. | Novel USP7 inhibitors for treating multiple myeloma |
| EP3870179A4 (en) | 2018-10-22 | 2022-11-23 | Dana Farber Cancer Institute, Inc. | USP7 ESCAPEMENT |
| JP2024526849A (ja) | 2021-07-20 | 2024-07-19 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | ユビキチン特異的プロテアーゼ７（ｕｓｐ７）を標的とする阻害剤 |
-
2018
- 2018-09-26 AU AU2018342089A patent/AU2018342089B2/en active Active
- 2018-09-26 CA CA3072353A patent/CA3072353A1/en active Pending
- 2018-09-26 JP JP2020515000A patent/JP7402792B2/ja active Active
- 2018-09-26 WO PCT/US2018/052797 patent/WO2019067503A1/en not_active Ceased
- 2018-09-26 EP EP18862773.1A patent/EP3687537A4/en active Pending
- 2018-09-26 US US16/650,727 patent/US11465983B2/en active Active
-
2022
- 2022-09-02 US US17/902,512 patent/US12692250B2/en active Active
-
2023
- 2023-09-01 JP JP2023142246A patent/JP2023164918A/ja active Pending
-
2025
- 2025-12-05 JP JP2025235397A patent/JP2026031721A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023164918A (ja) | 2023-11-14 |
| AU2018342089A1 (en) | 2020-02-27 |
| US11465983B2 (en) | 2022-10-11 |
| US20200347031A1 (en) | 2020-11-05 |
| JP2026031721A (ja) | 2026-02-24 |
| WO2019067503A1 (en) | 2019-04-04 |
| EP3687537A1 (en) | 2020-08-05 |
| US20230265070A1 (en) | 2023-08-24 |
| AU2018342089B2 (en) | 2024-07-11 |
| EP3687537A4 (en) | 2021-06-16 |
| JP7402792B2 (ja) | 2023-12-21 |
| JP2020535124A (ja) | 2020-12-03 |
| US12692250B2 (en) | 2026-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018342089B2 (en) | Novel USP7 inhibitors for treating multiple myeloma | |
| US12559457B2 (en) | Sulfonamide derivatives for protein degradation | |
| EP3459958B1 (en) | Process and intermediates for preparing prodrugs of pyridone amides useful as modulators of sodium channels | |
| CA3083228A1 (en) | Small molecule degraders that recruit dcaft15 | |
| EA030631B1 (ru) | 1,4-дизамещенные аналоги пиридазинхинолина и способы лечения состояний, связанных с smn-дефицитом | |
| KR20140085430A (ko) | 선택적이고 가역적 유비퀴틴 특이적 프로테아제 7의 저해제 | |
| JP2023516645A (ja) | Ｔｅａｄ阻害剤としてのヘテロ二官能性分子 | |
| CA3113547A1 (en) | Usp7 inhibition | |
| CA3075813A1 (en) | Small molecule inhibition of transcription factor sall4 and uses thereof | |
| EP2931710A1 (en) | Pyridazinones as daao enzyme inhibitors | |
| EP3989967B1 (en) | Compounds, compositions, and methods for protein degradation | |
| WO2016055858A1 (en) | Compounds and their use as bace inhibitors | |
| WO2023207447A1 (zh) | 吡咯并[2,3-d]嘧啶或吡唑并[3,4-d]嘧啶衍生物及其用途 | |
| WO2023179078A1 (zh) | 咪唑并[1,2-a]吡嗪或吡唑并[1,5-a]嘧啶衍生物及其用途 | |
| US20230312481A1 (en) | Substituted (phthalazin-1-ylmethyl)ureas, substituted n-(phthalazin-1-ylmethyl)amides, and analogues thereof | |
| WO2025007026A1 (en) | Heterobifunctional compounds and methods of use thereof | |
| HK40006287B (en) | Process and intermediates for preparing prodrugs of pyridone amides useful as modulators of sodium channels | |
| HK40006287A (en) | Process and intermediates for preparing prodrugs of pyridone amides useful as modulators of sodium channels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230925 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240920 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240920 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240920 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20240924 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241015 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241031 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250501 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250619 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250619 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW Effective date: 20250819 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250826 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250919 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250919 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251106 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251106 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251106 |